Acute Leukemias Update, Issue 1, 2020 (Audio Program)

Interview with Alexander Perl, MD

Track 1: Case: A woman in her early 70s with a history of triple-negative breast cancer receives venetoclax/azacitidine for secondary acute myeloid leukemia (AML)
Track 2: Nonspecific symptoms of AML at initial diagnosis
Track 3: Efficacy and safety of liposomal cytarabine/daunorubicin (CPX-351) in older patients with newly diagnosed AML
Track 4: Essential diagnostic workup and genetic testing in AML: Consideration of disease characteristics in treatment decision-making
Track 5: Differentiating therapy-related AML; treatment outcomes in patients with unfavorable, complex or monosomal karyotypes
Track 6: Prior treatments that increase the risk of therapy-related AML; factors to consider in selecting intensive versus nonintensive treatment for therapy-related disease
Track 7: Considering patient needs and preferences in choosing intensive versus nonintensive treatment
Track 8: Potential cure rates for patients with AML in different clinical scenarios
Track 9: Diagnostic workup for AML; importance of genetic alterations in treatment selection
Track 10: Workup for intermediate- or favorable-risk karyotypes to guide the decision to use gemtuzumab ozogamicin in AML
Track 11: Integrating the FDA reapproved agent gemtuzumab ozogamicin into therapy for AML: Outcomes from the Phase III ALFA-0701 trial
Track 12: Role of the hedgehog inhibitor glasdegib in front-line therapy for patients with AML not eligible for intensive induction chemotherapy
Track 13: Treatment of AML with venetoclax and a hypomethylating agent: Considerations for optimizing therapeutic benefit
Track 14: Prevention of tumor lysis syndrome in patients with AML receiving venetoclax-based therapy
Track 15: Efficacy of front-line venetoclax/azacitidine for AML
Track 16: Age- and fitness-based risk-benefit assessment when determining whether to administer venetoclax/azacitidine to patients with AML
Track 17: Monitoring for and mitigation of tumor lysis syndrome associated with venetoclax/azacitidine
Track 18: Management of myelosuppression associated with venetoclax in combination with a hypomethylating agent
Track 19: Case: A man in his mid-20s presents with hyperplasia, leukocytosis and fatigue and is diagnosed with AML with a FLT3 mutation
Track 20: Efficacy and safety results from the Phase III ADMIRAL trial of gilteritinib for relapsed or refractory AML; potential for moving gilteritinib into earlier lines of therapy
Track 21: FLT3 inhibitors as maintenance therapy: Optimal duration, quality of life and the ongoing Phase III BMT CTN 1506 trial
Track 22: Outcomes with gilteritinib as front-line therapy for AML with a FLT3 mutation
Track 23: Treatment options for older patients with AML with FLT3 mutations who are not candidates for intensive therapy
Track 24: Evidence supporting the use of IDH inhibitors for older patients with AML with IDH1/2 mutations
Track 25: Evolving treatment landscape in acute lymphoblastic leukemia (ALL); management paradigm for ALL in younger versus older patients or those with Philadelphia chromosome-positive disease
Track 26: Efficacy and safety of the bispecific T-cell engager blinatumomab as a salvage therapy option for relapsed or refractory ALL
Track 27: Chimeric antigen receptor (CAR) T-cell therapies in the third-line setting for patients with relapsed or refractory ALL: Efficacy outcomes and tolerability
Track 28: FDA approval of tisagenlecleucel for ALL; perspective on improving T-cell persistence and overcoming resistance to CAR T-cell therapy

Interview with Eunice Wang, MD

Track 1: Case: A woman in her early 60s with previously treated metastatic triple- negative breast cancer is diagnosed with AML with a FLT3-ITD mutation
Track 2: Molecular profiling in the diagnosis and treatment of AML
Track 3: Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation
Track 4: CPX-351 for secondary AML
Track 5: Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib
Track 6: Clinical experience with and tolerability of gilteritinib
Track 7: Activity of midostaurin in newly diagnosed AML with a FLT3 mutation
Track 8: Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation
Track 9: Significance of allelic ratio in AML with a FLT3-ITD mutation
Track 10: Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer
Track 11: Activity and safety of immune checkpoint inhibitors in patients with AML
Track 12: Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML
Track 13: Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib
Track 14: Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome
Track 15: Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice
Track 16: Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations
Track 17: Integration of venetoclax in combination with a hypomethylating agent into community practice
Track 18: Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics
Track 19: Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML
Track 20: Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission
Track 21: Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations
Track 22: Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL
Track 23: Tolerability and safety of blinatumomab and inotuzumab ozogamicin
Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine at
the University of Pennsylvania
Member, Leukemia Program
Abramson Cancer Center of
the University of Pennsylvania
Philadelphia, Pennsylvania
Eunice Wang, MD
Chief, Leukemia Service
Professor of Oncology
Hematologic Procurement Shared Resource
Department of Tumor Immunology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Neil Love, MD
Research To Practice
Miami, Florida